Compare BEEM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | PRPO |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | BEEM | PRPO |
|---|---|---|
| Price | $1.72 | $24.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 234.3K | 14.5K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,668,000.00 | $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $45.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $1.33 | $3.90 |
| 52 Week High | $4.04 | $28.50 |
| Indicator | BEEM | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 56.64 |
| Support Level | $1.81 | $23.92 |
| Resistance Level | $2.00 | $25.62 |
| Average True Range (ATR) | 0.12 | 1.34 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 19.44 | 66.75 |
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.